
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
As a practicing psychiatrist, you probably encounter a range of ethical dilemmas in your daily practice.
As a practicing psychiatrist, you probably encounter a range of ethical dilemmas in your daily practice. Psychiatric Times wants to go beyond the ethics lessons and find out how you would handle some hypothetical dilemmas. We invite you to take our




